W R Smythe

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Treatment of stage I and II non-small-cell lung cancer
    W R Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Control 8:318-25. 2001
  2. ncbi request reprint Treatment of stage I non-small cell lung carcinoma
    W Roy Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, TX, USA
    Chest 123:181S-187S. 2003
  3. ncbi request reprint Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
    W Roy Smythe
    Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Thorac Cardiovasc Surg 123:1191-8. 2002
  4. ncbi request reprint Surgical resection of non-small cell carcinoma after treatment for small cell carcinoma
    W R Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 71:962-6. 2001
  5. ncbi request reprint Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines
    A Pataer
    Department of Thoracic and Cardiovascular Surgery, and the Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Cardiovasc Surg 121:61-7. 2001
  6. ncbi request reprint Preoperative chemotherapy for lung cancer does not increase surgical morbidity
    M P Siegenthaler
    Department of Thoracic and Cardiovascular Surgery, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 71:1105-11; discussion 1111-2. 2001
  7. ncbi request reprint Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma
    I Mohiuddin
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Gene Ther 8:547-54. 2001
  8. ncbi request reprint Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters
    Hoon K Lee
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 57:1317-22. 2003
  9. ncbi request reprint Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter
    J B Putnam
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 69:369-75. 2000
  10. ncbi request reprint A single-institutional, multidisciplinary approach to primary sarcomas involving the chest wall requiring full-thickness resections
    G L Walsh
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Cardiovasc Surg 121:48-60. 2001

Detail Information

Publications52

  1. ncbi request reprint Treatment of stage I and II non-small-cell lung cancer
    W R Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Control 8:318-25. 2001
    ....
  2. ncbi request reprint Treatment of stage I non-small cell lung carcinoma
    W Roy Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, TX, USA
    Chest 123:181S-187S. 2003
    ..Primary radiation therapy should be considered for inoperable patients. The use of neoadjuvant or adjuvant radiation therapy in patients with stage I NSCLC is of unproven benefit...
  3. ncbi request reprint Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
    W Roy Smythe
    Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Thorac Cardiovasc Surg 123:1191-8. 2002
    ....
  4. ncbi request reprint Surgical resection of non-small cell carcinoma after treatment for small cell carcinoma
    W R Smythe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 71:962-6. 2001
    ..Development of non-small cell lung carcinoma (NSCLC) in patients previously treated for small cell carcinoma (SCLC/NSCLC) is well described; however, little is known about clinical outcome...
  5. ncbi request reprint Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines
    A Pataer
    Department of Thoracic and Cardiovascular Surgery, and the Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Cardiovasc Surg 121:61-7. 2001
    ..These data suggest that the gene transfer of proapoptotic Bcl-2 family members may represent a novel gene therapy strategy to treat mesothelioma...
  6. ncbi request reprint Preoperative chemotherapy for lung cancer does not increase surgical morbidity
    M P Siegenthaler
    Department of Thoracic and Cardiovascular Surgery, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 71:1105-11; discussion 1111-2. 2001
    ..CONCLUSIONS: C+S did not significantly affect morbidity or mortality overall, based on clinical stage, postoperative stage, or extent of resection. The potential for enhanced survival in resectable NSCLC justifies continued study of C+S...
  7. ncbi request reprint Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma
    I Mohiuddin
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Gene Ther 8:547-54. 2001
    ..Synergy may be due to the ability of SB to decrease bcl-xl with marked increases in PAP engendered by PAGT. Combination therapy with agents that down-regulate AAP in addition to PAGT may prove useful clinically...
  8. ncbi request reprint Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters
    Hoon K Lee
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 57:1317-22. 2003
    ..To clarify the relationship between the percentage of lung receiving low radiation doses with concurrent chemotherapy and the occurrence of postoperative pulmonary complications in the treatment of esophageal carcinoma...
  9. ncbi request reprint Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter
    J B Putnam
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 69:369-75. 2000
    ..Outpatient management of malignant pleural effusion with a PC may reduce length of stay and early (7-day) charges compared with inpatient management with chest tube and sclerosis...
  10. ncbi request reprint A single-institutional, multidisciplinary approach to primary sarcomas involving the chest wall requiring full-thickness resections
    G L Walsh
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Cardiovasc Surg 121:48-60. 2001
    ..CONCLUSIONS: A combined aggressive multidisciplinary approach to primary sarcomas of the chest wall resulted in no treatment-related deaths and a cumulative 5-year survival of 64% in patients referred to our tertiary care cancer center...
  11. ncbi request reprint Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection
    Banke Agarwal
    Department of GI Medicine and Nutrition, Medical Oncology and Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, Texas, USA
    Am J Gastroenterol 99:1258-66. 2004
    ..Based on these data, we reevaluated the role of EUS in identifying patients who maximally benefit from surgical esophageal resection after preoperative chemoXRT...
  12. pmc Treatment outcomes of resected esophageal cancer
    Wayne Hofstetter
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg 236:376-84; discussion 384-5. 2002
    ..To assess the evolution of treatment and outcome for resected esophageal cancer at a single institution...
  13. ncbi request reprint Primary lymphoepithelioma of the esophagus
    Freddy Angulo-Pernett
    Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 76:603-5. 2003
    ..The tumor exhibited classic histologic and immunohistochemical features of lymphoepithelioma, and was successfully treated with neoadjuvant chemotherapy and irradiation followed by surgical resection...
  14. ncbi request reprint Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma
    Mustafa K Ozvaran
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Mol Cancer Ther 3:545-50. 2004
    ..We sought to determine whether antisense oligonucleotides directed at the bcl-xl gene product would augment response to a conventional chemotherapeutic agent in human mesothelioma cell lines...
  15. doi request reprint Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts
    James E Littlejohn
    Department of Molecular and Cellular Medicine, Texas A and M Health Science Center, College of Medicine, College Station, TX, USA
    Int J Cancer 123:202-8. 2008
    ..More notably, the combination of Bcl-xL ASO and cisplatin extends survival in an orthotopic tumor xenograft model...
  16. ncbi request reprint Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma
    Anesa Ahamad
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 55:768-75. 2003
    ..Intensity-modulated radiation therapy (IMRT) has the potential to overcome these geometric/dosimetric constraints...
  17. ncbi request reprint Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma
    X X Cao
    Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Respir Cell Mol Biol 25:562-8. 2001
    ..Additional study of the therapeutic benefit of targeting bcl-xl gene expression in mesothelioma is warranted...
  18. ncbi request reprint Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients
    Ara A Vaporciyan
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, TX 77030, USA
    J Thorac Cardiovasc Surg 127:779-86. 2004
    ..The purpose of this study was to identify risk factors associated with the onset of atrial fibrillation after thoracic surgery to allow more targeted interventions in patients with the highest risk...
  19. ncbi request reprint 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma
    Stephen G Swisher
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:1776-85. 2004
    ..Preliminary reports suggest that FDG-PET may be predictive of the response of esophageal carcinoma patients to preoperative CRT...
  20. ncbi request reprint Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer
    Stephen G Swisher
    Department of Thoracic Surgery, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Thorac Surg 78:1152-60; discussion 1152-60. 2004
    ....
  21. ncbi request reprint Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 79:391-7; discussionn 391-7. 2005
    ..Preoperative chemotherapy and radiation therapy are often administered to patients with esophageal cancer. Despite an aging population, little data exist regarding feasibility of preoperative therapy in elderly patients...
  22. ncbi request reprint Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications
    Jeremy J Erasmus
    Departments of Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, Houston, Tex, USA
    J Thorac Cardiovasc Surg 129:1364-70. 2005
    ..We evaluate the use of integrated computed tomography-positron emission tomography in patients with malignant pleural mesothelioma who are being considered for extrapleural pneumonectomy...
  23. ncbi request reprint Extended surgical staging for potentially resectable malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 80:1988-92; discussion 1992-3. 2005
    ..We evaluated the role of extended surgical staging procedures, which generally includes a combination of laparoscopy, peritoneal lavage, and mediastinoscopy, to more precisely stage patients with MPM...
  24. ncbi request reprint Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 84:1685-92; discussion 1692-3. 2007
    ..To improve local control, we have used intensity-modulated radiation therapy (IMRT) as it allows better dose distribution to regions at risk of recurrence as well as reduced radiation to surrounding organs...
  25. ncbi request reprint The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution
    Linda W Martin
    Departments of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    J Thorac Cardiovasc Surg 130:1601-10. 2005
    ..To determine which treatment factors are associated with improved survival, we evaluated outcomes for these patients at our institution over a 16-year period...
  26. ncbi request reprint Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:350-7. 2007
    ..To determine the incidence of fatal pulmonary events after extrapleural pneumonectomy and hemithoracic intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma...
  27. ncbi request reprint Malignant mesothelioma: natural history, pathologic features and future therapies
    Luis H Camacho
    Phase I Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Med 120:e7-9. 2007
  28. doi request reprint A possible association between aprotinin and improved survival after radical surgery for mesothelioma
    Peter H Norman
    Department of Anesthesiology and Pain Medicine, Unit 409, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 115:833-41. 2009
    ..In this prospective, randomized, placebo-controlled, double-blind trial, the authors investigated whether aprotinin decreased blood loss in patients who underwent this operation...
  29. ncbi request reprint Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer
    Stephen G Swisher
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:120-7. 2003
    ..To evaluate the long-term outcome of chemotherapy, chemoradiotherapy, and surgery for patients with locoregionally advanced esophageal cancer...
  30. ncbi request reprint Incidence of major pulmonary morbidity after pneumonectomy: association with timing of smoking cessation
    Ara A Vaporciyan
    Department of Thoracic and Cardiovascular Surgery and Medical Informatics, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Thorac Surg 73:420-5; discussion 425-6. 2002
    ..The purpose of this study was to identify preoperative and perioperative factors associated with the development of MPEs after pneumonectomy to help predict which patients are at increased risk for MPEs...
  31. ncbi request reprint The risk of second primary tumors after resection of stage I nonsmall cell lung cancer
    David Rice
    Department of Thoracic and Cardiovascular Surgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 76:1001-7; discussion 1007-8. 2003
    ..The overall effect of SPLC on survival after resection of stage I NSCLC is unknown. Here we report the incidence, management, and outcome of SPLC in a large prospective cohort of patients who underwent careful follow-up...
  32. ncbi request reprint Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation
    Kenneth M Forster
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 55:606-16. 2003
    ..We describe a novel technique for implementing intensity-modulated radiotherapy (IMRT) to deliver higher doses to treat the full extent of these complex target volumes...
  33. ncbi request reprint Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest
    Anesa Ahamad
    Department of Radiation Oncology, Section of Thoracic Molecular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:476-84. 2003
    ..We report how these geometric/dosimetric constraints were overcome by exploiting intensity-modulated radiotherapy in the first cohort patient...
  34. ncbi request reprint Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy
    Stephen G Swisher
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Cardiovasc Surg 123:175-83. 2002
    ..A subset of these patients have local relapse without distant metastases and therefore have no other curative intent treatment option but salvage esophagectomy...
  35. ncbi request reprint Current therapy for malignant mesothelioma
    W Roy Smythe
    Multidisciplinary Mesothelioma Thoracic Oncology Program, Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, USA
    Curr Oncol Rep 4:305-13. 2002
    ..The prospects for newer modalities, ie molecular and biologic therapies, are also highlighted, including results of both preclinical and early clinical research...
  36. ncbi request reprint The potential role of aprotinin in the perioperative management of malignant tumors
    Ara A Vaporciyan
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 445, Houston, TX 77030, USA
    J Am Coll Surg 198:266-78. 2004
  37. ncbi request reprint Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:3495-501. 2005
    ..To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma...
  38. ncbi request reprint Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells
    Hongbo Zhu
    Department of Thoracic and Cardiovascular Surgery, Unit 445, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 4:451-6. 2005
    ..These results suggest that down-regulation of Bcl-XL protein expression might provide a new treatment strategy for human 5-FU-resistant colon cancer therapy...
  39. ncbi request reprint The role of Bcl-2 family members in non-small cell lung cancer
    Jonathan C Daniel
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Thorac Cardiovasc Surg 16:19-27. 2004
    ..In addition, the current experience with clinical trials involving Bcl-2 down-regulation in solid organ tumors will be summarized...
  40. ncbi request reprint Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications
    Faisal Bakaeen
    The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    Ann Thorac Surg 84:982-6. 2007
    ..The purpose of this study was to examine the effect of aprotinin on blood loss in extrapleural pneumonectomy and to identify potential treatment-related complications...
  41. ncbi request reprint Cadherin and catenin expression in normal human bronchial epithelium and non-small cell lung cancer
    W R Smythe
    M D Anderson Cancer Center, Department of Thoracic and Cardiovascular Surgery, The University of Texas, Houston 77030, USA rsmythenotes mdacc tmc edu
    Lung Cancer 24:157-68. 1999
    ....
  42. ncbi request reprint Phosphatase and tensin analog gene overexpression engenders cellular death in human malignant mesothelioma cells via inhibition of AKT phosphorylation
    Imran Mohiuddin
    Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 9:310-6. 2002
    ..A downstream target of PTEN is AKT, a serine-threonine kinase that when activated inhibits apoptosis. We sought to determine whether PTEN overexpression in mesothelioma cells would engender hypophosphorylation of AKT and apoptosis...
  43. ncbi request reprint Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction
    Anthony J Ascioti
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Tex 77030, USA
    J Thorac Cardiovasc Surg 130:1391-8. 2005
    ..Few reports describe this technique in patients with cancer. We report our initial experience with "supercharged" pedicled jejunum as an alternative conduit for total esophageal reconstruction...
  44. pmc Adenoviral transfer of mda-7 leads to BAX up-regulation and apoptosis in mesothelioma cells, and is abrogated by over-expression of BCL-XL
    Xiaobo X Cao
    Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Mol Med 8:869-76. 2002
    ..We evaluated cell growth, apoptosis and tumor suppressor characteristics following forced expression of this gene in mesothelioma cell lines...
  45. ncbi request reprint Gene therapy of lung cancer
    Jonathan C Daniel
    Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA
    Semin Surg Oncol 21:196-204. 2003
    ....
  46. ncbi request reprint Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA
    Hongbo Zhu
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 4:393-7. 2005
    ..Together, our data suggest that simultaneous triggering of the death receptor and mitochondrial apoptotic pathways leads to enhanced induction of apoptosis, which makes it potentially useful for the treatment of resistant cancers...
  47. ncbi request reprint Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma
    Philip A Rascoe
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderso Cancer Center, Houston, TX 76508, USA
    J Thorac Cardiovasc Surg 130:393-400. 2005
    ..Phosphoinositide-3 kinase is activated by cell-surface receptor tyrosine kinases. We sought to determine which receptors are present in mesothelioma and their role in cellular survival and phosphoinositide-3 kinase signaling...
  48. ncbi request reprint Radiotherapy for mesothelioma
    Craig W Stevens
    Division of Radiation Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Hematol Oncol Clin North Am 19:1099-115, vii. 2005
    ..However, the preponderance of death from distant metastases makes the development of better systemic therapy essential. Better therapy also must be developed for patients who are not candidates for extrapleural pneumonectomy...
  49. ncbi request reprint Malignant pleural mesothelioma--an update
    Duncan J Stewart
    University Department of Oncology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
    Int J Occup Environ Health 10:26-39. 2004
    ..With new treatments based on better understanding of the biology of the disease, there is cautious optimism for the future for patients with malignant pleural mesothelioma...
  50. ncbi request reprint Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma
    Xiaobo Cao
    Section of Surgery Research, Department of Surgery, Scott and White Memorial Hospital and Clinic, 2401 South 31st Street, Temple, TX 76508, USA
    Cancer Biol Ther 6:246-52. 2007
    ....
  51. ncbi request reprint Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models
    Judith W Cook
    Section of Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Lung Cancer 42:263-74. 2003
    ..These studies demonstrate that suramin may have the potential to provide effective therapy for MM, and that further studies are necessary to elucidate the survival advantage of suramin mediated MM growth inhibition...
  52. ncbi request reprint Prospective randomized study evaluating a biodegradable polymeric sealant for sealing intraoperative air leaks that occur during pulmonary resection
    Mark S Allen
    Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 77:1792-801. 2004
    ..To evaluate the safety and effectiveness of a new biodegradable polymeric sealant to close intraoperative air leaks after pulmonary resection...